Sean Peter Johnson1, Rajiv Ramasawmy2, Adrienne Campbell2, Mathew Robson1, Mario Mazzantini1, Vineeth Rajkumar1, Barbara Pedley1, Mark Lythgoe2, Simon Walker-Samuel2
1Cancer Institute, UCL, London, United Kingdom; 2Centre for Advanced Biomedical Imaging, UCL, London, United Kingdom
Liver metastases are the major cause of mortality in patients with colorectal carcinoma (CRC). The vascular disrupting agent OXi4503 has been tested in phase I clinical trials of metastatic disease with R2* recommended as a biomarker of response. R2* response however may not accurately reflect response to treatment exclusively. Arterial spin labeling (ASL) is able to assess changes in tumour perfusion. We show that in a clinically relevant liver metastatic model of CRC (n=10 metastases) acquisition of combined R2* and ASL at baseline and 90min following 40mg/kg OXi4503 i.v. is more adequate at assessing response to treatment.